Enliven Therapeutics (NASDAQ:ELVN) Announces Earnings Results, Beats Expectations By $0.09 EPS

Posted by Brenda Bartman on Nov 5th, 2026

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) announced its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09, FiscalAI reports.

Enliven Therapeutics Stock Down 5.2%

ELVN traded down $2.46 during midday trading on Thursday, hitting $44.79. The stock had a trading volume of 1,585,854 shares, compared to its average volume of 1,673,929. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $62.32. The business has a fifty day moving average of $47.48 and a 200 day moving average of $42.96.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of research reports. JPMorgan Chase & Co. assumed coverage on shares of Enliven Therapeutics in a research note on Thursday, October 1st. They issued an “overweight” rating and a $75.00 price target for the company. William Blair initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating for the company. Guggenheim reiterated a “buy” rating on shares of Enliven Therapeutics in a research report on Thursday, October 8th. Mizuho increased their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Finally, Barclays started coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price target on the stock. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $75.44.

Read Our Latest Stock Analysis on Enliven Therapeutics

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the completion of the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 31,054 shares of company stock valued at $1,493,823. Company insiders own 3.00% of the company’s stock.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.